Lovro Kramer
Jožef Stefan Institute
9 Papers
6 Citations
Lovro Kramer is an academic researcher from Jožef Stefan Institute. The author has contributed to research in topics: Cathepsin & Targeted drug delivery. The author has an hindex of 6, co-authored 7 publications.
Chat about Author
Papers
The Future of Cysteine Cathepsins in Disease Management.
TL;DR: This work focuses here on inflammation-associated diseases because dysregulation of the immune system accompanied by elevated cathepsin activity is a common feature of these conditions.
174
Biocompatible nano-gallium/hydroxyapatite nanocomposite with antimicrobial activity.
TL;DR: The investigated material is promising for the prevention of implantation–induced infections that are frequently caused by P. aeruginosa, and is the first report of a biomaterial composite with gallium nanoparticles.
58
In Vivo Imaging of Mouse Tumors by a Lipidated Cathepsin S Substrate
Hai-Yu Hu,Divya Vats,Matej Vizovišek,Lovro Kramer,Catherine Germanier,K. Ulrich Wendt,Markus Rudin,Boris Turk,Boris Turk,Oliver Plettenburg,Carsten Schultz +10 more
TL;DR: The lipidated probe provided a prolonged and strongly fluorescent signal in tumors when compared to the very similar non-lipidated probe, demonstrating that non-invasive tumor identification is feasable.
55
Non-invasive in vivo imaging of tumour-associated cathepsin B by a highly selective inhibitory DARPin.
Lovro Kramer,Miha Renko,Janja Završnik,Dušan Turk,Markus A. Seeger,Olga Vasiljeva,Markus G. Grütter,Vito Turk,Boris Turk +8 more
TL;DR: This approach validates cathepsin B as a promising diagnostic and theranostic target in cancer and other inflammation-associated diseases.
49
Designing Ga(III)-containing hydroxyapatite with antibacterial activity
TL;DR: In this paper, the incorporation of Ga3+ ions into hydroxyapatite to achieve an effective biological response against P. aeruginosa and cytocompatibility with L929 mouse fibroblasts was examined in vitro.
34